Bladder Cancer

Lung Cancer

Based on the phase II study BLC2001, erdafitinib has been granted a breakthrough therapy designation by the FDA for the treatment of metastatic urothelial carcinoma, according to Janssen, the manufacturer of the oral pan-FGFR tyrosine kinase inhibitor.

<em>Targeted Therapies in Oncology</em>, an oncology resource that provides oncology professionals with cutting-edge research, data, and treatment strategies surrounding molecular and immune system targets, welcomes&nbsp;Arjun V. Balar, MD,&nbsp;as its editor-in-chief.

A supplemental new drug application for Blue Light Cytoscopy with Cysview, a procedure for detecting bladder cancer, was recently approved by the FDA.

Lung Cancer

The FDA has approved a 4-week dosing schedule for the PD-1 inhibitor nivolumab (Opdivo) across several indications.

Cisplatin-based chemotherapy has been and remains the standard of care in advanced urothelial carcinoma, and can provide a cure for a small subset of these patients.

Updated findings from the phase III KEYNOTE-045 trial confirmed the benefit of&nbsp;pembrolizumab (Keytruda) compared with chemotherapy in pretreated patients with locally advanced or recurrent urothelial cancer. Two-year follow-up of the trial presented at the 2018 Genitourinary Cancers Symposium demonstrated that overall survival was improved with pembrolizumab.

During the 2018 Genitourinary Cancers Symposium, Monika Joshi, MD, assistant professor, Penn State Hershey Medical Center, shared results of a phase Ib study of durvalumab (Imfinzi) and radiation therapy (DUART) followed by adjuvant durvalumab in patients with bladder cancer.

Arjun Balar, MD, recently shared the treatment considerations and decisions he makes when treating patients with advanced bladder cancer.

According to results from the phase I JAVELIN Solid Tumor study recently published in the Lancet Oncology, the PD-L1 inhibitor avelumab (Bavencio) induced an overall response rate of 17% in patients with platinum-refractory metastatic urothelial carcinoma.

Pembrolizumab (Keytruda) has been approved in Japan for the treatment&nbsp;of patients with radically unresectable urothelial carcinoma who progressed after cancer chemotherapy, according to Merck, the manufacturer of the PD-1 inhibitor.